COVID-19: Vaccines and Therapeutics
More than 200,000 of our friends, family members, fellow citizens and front-line workers have succumbed to COVID-19 since March. To put that in context, that’s approximately the same as the population of Salt Lake City, Utah.
The Centers for Disease Control and Prevention awarded $200 million in Coronavirus Aid, Relief, and Economic Security Act funds to help states, territories and other jurisdictions prepare to distribute and administer COVID-19 vaccine.
Johnson & Johnson said that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.
This Member Advisory summarizes the federal strategy for the public distribution of COVID-19 vaccines.
The AHA has launched a new webpage that houses AHA-developed tools, as well as resources from the federal government and other stakeholders related to a COVID-19 vaccine.
This webpage is intended to help keep the field informed of important updates related to vaccine development, distribution, utilization protocols, supply chain and many other issues, through AHA-developed tools, as well as resources from the federal government and other stakeholders.
AHA comments on the National Academies of Sciences, Engineering and Medicine’s Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine.
The AHA urged the National Academies of Sciences, Engineering and Medicine to adopt a unified set of guidelines to account for the variables associated with all issues of the eventual allocation of COVID-19 vaccine allocation.
The National Academies of Sciences, Engineering, and Medicine today released for public comment a discussion draft of a preliminary framework to assist policymakers in planning for equitable allocation of a vaccine against COVID-19.
Download this infographic to learn how the AHA is working to make sure hospitals and health systems on the front lines have the supplies and equipment they need.